We were pleased to attend the Longevity Summit 2025 at the Buck Institute for Research on Aging, a vibrant gathering of leaders across aging science, biotechnology, and translational research, united by a shared commitment to advancing healthy aging.
We were delighted to see Dr. Eric Verdin, President & CEO of the Buck Institute, present compelling new data on the role of CD38 in the aging brain and its contribution to cognitive decline.
The presentation also highlighted data generated using NTX-748, Juvenescence®’s proprietary, highly selective and potent small-molecule CD38 inhibitor.
This work reflects the strength of the ongoing collaboration between the Verdin Lab at the Buck Institute and Juvenescence, demonstrating how impactful partnerships can accelerate scientific discovery and therapeutic innovation.
A meaningful highlight for both CD38 biology and the longevity field.
hashtagLongevitySummit hashtagBuckInstitute hashtagAgingResearch hashtagHealthyAging hashtagLongevity hashtagCD38 hashtagNAD hashtagNeuroscience hashtagBiotech hashtagJuvenescence hashtagNapaTherapeutics hashtagResearch hashtagCollaboration hashtagTeamScience